Fispemifene program focus returning to LUTS (lower urinary tract symptoms)
Our US development and licensing partner, Apricus Biosciences Inc., yesterday announced (link to press release) their phase 2b results of Fispemifene for the treatment of sexual dysfunction in men with secondary hypogonadism. Although the testosterone levels were significantly elevated, the symptomatic endpoints were not met in this study population. Fispemifene was well tolerated by the […]